For the year ending 2025-12-31, ABVC had $463,170 increase in cash & cash equivalents over the period.
| Cash Flow | 2025-12-31 |
|---|---|
| Loan to related parties | 1,406,022 |
| Repayment from related parties | 203,026 |
| Transaction costs for acquiring land | 5,794 |
| Net cash used in investing activities | -1,208,790 |
| Proceeds from private placement | 3,305,303 |
| Proceeds from exercise of warrants | 991,366 |
| Proceeds from convertible notes payable third parties | 499,010 |
| Repayment of convertible notes payable third parties | 277,284 |
| Proceeds from convertible notes payable related parties | 390,000 |
| Repayment of convertible notes payable related parties | 150,000 |
| Repayment of short-term bank loans | 120,400 |
| Proceeds from related party payables | 0 |
| Proceeds from issuance of warrants | 0 |
| Repurchase of treasury stocks | 0 |
| Proceeds from issuance of a promissory note | 0 |
| Proceeds from common stock subscription | 0 |
| Net cash provided by financing activities | 4,637,995 |
| Effect of exchange rate changes on cash and cash equivalents and restricted cash | 20,264 |
| Inventory write-down | 11,460 |
| Other non-cash expenses, net | 351,085 |
| Amortization of right-of-use asset | 479,504 |
| Inventory | 11,460 |
| Prepaid expenses and other current assets | 71,653 |
| Due from related parties | 136,501 |
| Accrued expenses and other current liabilities | 152,207 |
| Contract liabilities | -68,515 |
| Tenant security deposit | -16,865 |
| Taxes payables | 11,964 |
| Operating lease liabilities | -474,479 |
| Net loss | -8,376,959 |
| Depreciation | 25,330 |
| Stock-based compensation | 4,142,816 |
| Loss on investment in equity securities | -192,759 |
| Loss on impairment of equity investment | -803,008 |
| Provision for doubtful accounts | 0 |
| Net cash used in operating activities | -2,986,299 |
| Net increase in cash and cash equivalents and restricted cash | 463,170 |
| Beginning | 863,815 |
| Ending | 1,326,985 |
ABVC BIOPHARMA, INC. (ABVC)
ABVC BIOPHARMA, INC. (ABVC)